Protein expression enhancing polypeptides

Inventors

HISHIYA, Akinori • Koya, Keizo • Rastelli, Luca

Assignees

Sola Biosciences LLC

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-9758807-B2

Patent

Publication Date

2017-09-12

Expiration Date


Abstract

Fusion proteins comprising a protein expression enhancing polypeptide linked to a target protein binding domain and nucleic acid molecules encoding such fusion proteins are described for use in enhancing expression and/or location of a targeted protein of interest, for restoring lost functions in cells, and for treating disease. Additional fusion proteins comprising a target protein of interest modified with a fusion partner comprising a protein expression enhancing polypeptide are also disclosed.

Core Innovation

The invention provides a fusion protein comprising a protein expression enhancing polypeptide (PEEP) domain linked to a target protein binding domain. The target protein binding domain is a protein or binding domain thereof that specifically binds a target protein of interest. Co-expression of the fusion protein with the target protein of interest bound by the target protein binding domain results in an enhanced level of expression of the target protein of interest compared to expression in the absence of the fusion protein.

The PEEP domain is selected from an isolated J domain of a J protein, a J domain analog polypeptide comprising the amino acid sequence of formula I, or a decapeptide selected from SEQ ID NOs:49, 50, 51, and 52, or from IKKAYKLALQ, IKKAYRLALQ, IKKAYRKALQ, and IKKAYRKLLQ. The J domain analog polypeptide is defined by residue-position constraints in formula I, including permitted amino acids at X1 and permitted amino acid or dipeptide sets at X2-X3, X4, X5-X7, and X8-X9.

The target protein binding domain includes antibody antigen-binding sites, antibody antigen-binding fragments, antibody binding proteins, Fc-binding proteins such as Protein A, Protein G, or HSV-1 gE, Fc-binding peptides, PDZ domains, and receptor binding domains. The description includes unmodified co-expression of secreted proteins with Erdj3 J-domain or minimal J-domain fragments fused to target-binding domains such as Protein A/G/L or Fc-binding peptides.

The examples include Fc targets such as IL13Rβ2TF, IL13Rβ2TF-Fc, TNFR1TF-Fc, α1AT-Fc, IgG1 anti-IL8, VEGF antibody bevacizumab, TNFα antibody adalimumab, and AATZ-Fc. The description states that co-expression yields enhanced intracellular and secreted levels of the target proteins and that secretion is restored for unstable or ER-retained proteins.

Claims Coverage

The independent claim coverage includes a fusion protein linking a protein expression enhancing polypeptide (PEEP) to a target protein binding domain, with a functional requirement that co-expression enhances target protein expression. The inventive features are centered on the PEEP definition, the binding domain requirement, and the enhanced-expression outcome.

Protein expression enhancing polypeptide linked to target protein binding domain

A fusion protein comprising a protein expression enhancing polypeptide (PEEP) domain linked to a target protein binding domain that specifically binds a target protein of interest.

J-domain or defined J-domain analog PEEP

The PEEP is selected from an isolated J domain of a J protein, a J domain analog polypeptide comprising the amino acid sequence of formula I, or a decapeptide selected from SEQ ID NOs:49, 50, 51, and 52, or from IKKAYKLALQ, IKKAYRLALQ, IKKAYRKALQ, and IKKAYRKLLQ.

Enhanced expression of the bound target protein upon co-expression

Co-expression of the fusion protein with the target protein of interest that is bound by the target protein binding domain results in an enhanced level of expression of the target protein of interest compared to the level of expression in the absence of the fusion protein.

Target protein binding domain that specifically binds the target protein of interest

The target protein binding domain is a protein or binding domain thereof that specifically binds the target protein of interest, including antibody antigen-binding sites, antibody antigen-binding fragments, antibody binding proteins, Fc-binding proteins such as Protein A, Protein G, or HSV-1 gE, Fc-binding peptides, PDZ domains, and receptor binding domains.

Protection is directed to a PEEP–binding-domain fusion protein defined by an isolated J domain, a formula-constrained J-domain analog, or specified decapeptides, together with the requirement that co-expression enhances target protein expression.

Stated Advantages

Enhanced level of expression of the target protein of interest compared to expression in the absence of the fusion protein.

Enhanced intracellular and secreted levels of the target proteins.

Restored secretion for unstable or ER-retained proteins.

Documented Applications

Co-expression of the fusion protein with a target protein of interest to enhance expression and secretion of secreted proteins, including Fc targets and antibodies.

Restoring secreted protein function in cells of a mammalian subject by inserting an exogenous nucleic acid encoding a fusion protein whose target protein binding domain binds the native secreted protein, where co-expression enhances secretion of the native protein to provide the protein function to the cells of the subject.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.